

7 February 2025

Ms Melissa Kostopoulos
Listing Advisor
Listings Compliance
ASX Limited
525 Collins Street
Melbourne VIC 3000

By email: listingscompliancemelbourne@asx.com.au

Dear Melissa

Response to ASX Price Query – Cleo Diagnostics Limited (ASX: COV)

Further to your correspondence dated today 7 February 2025 regarding the change in the price of the securities of Cleo Diagnostics Limited (“COV” and “the Company”) from a low of \$0.35 to a high of \$0.44 as of today, and reference to the volume of shares traded, I wish to respond as follows:

1. No.
2. No.

However, COV wishes to highlight that it has a patented 95 specificity / 95 sensitivity high performing Ovarian Cancer detection technology backed by a strong evidence base (See ASX Announcements 6 November 2023, 25 March 2024, and 29 May 2024). The Company is currently progressing clinical trials in the U.S. that will enable submission to the Food and Drug Administration (FDA) later this year to obtain approval to enter its first patient market.

The Company would also like to acknowledge that this week marks the commencement of Ovarian Cancer Awareness Month with broad media coverage noting the stark reality that Ovarian Cancer is the deadliest women’s cancer, having a five-year survival rate of just 49%, compared to 92% for breast cancer.

Cleo Diagnostics is the only known medical technology company on the ASX focussed on the development of its simple and accurate blood test for the early diagnosis of Ovarian Cancer.

3. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
4. It is confirmed that the responses to the questions above have been authorised and approved by the Board of the Company.

Please do not hesitate to contact the writer with any queries relating to this matter during office hours on 03 9614 0600.

Yours sincerely



Pauline Moffatt
Company Secretary

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors
Chair and Non-Executive Director: **Adrien Wing**
Chief Executive Officer and Executive Director: **Dr Richard Allman**
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor: **Professor Tom Jobling**
Non-Executive Director: **Lucinda Nolan**

cleodx.com



7 February 2025

Reference: ODIN105955

Ms Pauline Moffatt
Company Secretary
Cleo Diagnostics Ltd
Level 2, 480 Collins Street
Melbourne, Vic 3000

By email: pmoffatt@northernstargroup.com.au

Dear Ms Moffatt

Cleo Diagnostics Ltd ('COV'): Price - Query

ASX refers to the following:

- A. The change in the price of COV's securities from a low of \$0.35 to a high of \$0.44c today.
- B. The significant increase in the volume of COV's securities traded today.

Request for information

In light of this, ASX asks COV to respond separately to each of the following questions and requests for information:

1. Is COV aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

If the answer to question 1 is "yes".

- (a) Is COV relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in COV's securities would suggest to ASX that such information may have ceased to be confidential and therefore COV may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
2. If the answer to question 1 is "no", is there any other explanation that COV may have for the recent trading in its securities?
 3. Please confirm that COV is complying with the Listing Rules and, in particular, Listing Rule 3.1.
 4. Please confirm that COV's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of COV with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AEDT Monday, 10 February 2025**. You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, COV's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require COV to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in COV's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in COV's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to COV's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that COV's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Regards

ASX Compliance